Provider review
SexyMD Review: One Page, Two Answers to How Often You Inject
SexyMD's microdose page explains that the approach works by delivering the medication twice a week. Its instructions tab, on the same page, says once-weekly. Both were on screen in the same session. Everything else here — a plan-length price table where the plan length changes nothing, a badge saying 800+ women beside counters claiming tens of thousands of orders in a day — is ordinary marketing noise. The dosing frequency is not.
Its microdose page explains the therapy as a twice-weekly injection and instructs a once-weekly one, in the same session.
Worth trusting if
- You have already been prescribed a regimen elsewhere and are pricing a refill
- You want prices visible before an intake, which they are
Be skeptical if
- You are relying on the page to tell you how often to inject, because it gives two answers
- You are choosing a microdose plan length for a discount, because all three cost the same
- You want to know which pharmacy fills your prescription, because none is named
Compounded only
No trial for this use
Not named
None found
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens sexymd.com. A link is not a recommendation to take anything.
Provenance
What SexyMD actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Microdose GLP-1 + GIP — $259 a month at 4, 8 and 12 weeks alike — the plan-length table has three rows and one price.
- Microdose GLP-1 — $179 a month at 4, 8 and 12 weeks alike, in the same three-row table.
Evidence
Has the molecule been tested for what it is sold for?
One row per product, graded on how far the published human evidence goes for the MOLECULE inside it, for the use it is sold for — not for the molecule in general, and never a claim about this seller. Nobody trials a compounded preparation; what a trial can tell you is whether the molecule has been tested for the thing it is being advertised to do. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
0
Molecules with human evidence
For the use they are sold for, out of 2 products reviewed here. The evidence belongs to the molecule, not to SexyMD.
0
Registry records cited
Each read live from ClinicalTrials.gov, never from memory. None of them tested this company's product.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from SexyMD’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
Microdose GLP-1 + GIPTirzepatide · Compounded (503A)No trial supports this claim
“GLP-1 quiets the hunger. GIP changes the way your body holds and uses fat. Together they create a shift you feel before you can explain it. The microdose approach delivers this twice a week so your body receives steady, consistent support without the intensity of a single large dose. Gentler does not mean less powerful. It means smarter. [HOW TO USE:] Once-weekly subcutaneous injection, on the same day each week (unless instructed otherwise by your physician).”
Read on the SexyMD site, September 2026
No trial for this use
What the trials show for Tirzepatide
As of September 2026, no completed randomized trial has tested a microdosed tirzepatide regimen, at any frequency. Searched on ClinicalTrials.gov with no status filter, "microdose tirzepatide" and "low-dose tirzepatide" each return zero studies, while a bare "tirzepatide" search in the same pass returns 293 records — so the zeros are a finding rather than a broken search. Every trial in the program, SURMOUNT-1 included, used a once-weekly subcutaneous injection at a titrated dose, and none tested a twice-weekly schedule or a dose below the titration floor.
Before the evidence question there is a plainer one: how often is a patient meant to inject this? The page answers twice, differently. Its explanation of why microdosing works rests on delivering the medication "twice a week"; its instructions tab says "once-weekly subcutaneous injection, on the same day each week". Both were on screen in the same session. That is not a marketing inconsistency — it is two different answers to a dosing question, on the page selling the injection. On the evidence itself: no completed trial has tested a microdosed tirzepatide regimen at any frequency, so neither schedule has anything behind it. The mechanism sentences are the familiar ones stated with unusual confidence — "a shift you feel before you can explain it" is not a claim that can be checked at all.1
Microdose GLP-1Semaglutide · Compounded (503A)No trial supports this claim
“The Quiet Shift. Same powerful GLP-1 mechanism, gentler on your body. Designed for women who want to ease in or maintain results with a lighter touch. May help support a gradual, comfortable introduction to GLP-1 therapy.”
Read on the SexyMD site, September 2026
No trial for this use
What the trials show for Semaglutide
As of September 2026, no completed randomized trial has tested a microdosed semaglutide regimen. Searched on ClinicalTrials.gov with no status filter, "microdose semaglutide" and "low-dose semaglutide" return zero studies, while a bare "semaglutide" search in the same pass returns hundreds. The STEP program titrated to a therapeutic dose and measured body weight; no trial has reported what a dose held below that titration does, or whether it does anything.
"Same powerful GLP-1 mechanism, gentler on your body" is the whole microdosing proposition in eight words, and it asserts two things at once — that the effect is preserved and the burden reduced. Neither has been tested. A dose held below the studied titration has not been shown to keep the mechanism, and no trial has compared side-effect burden between a microdose and a standard dose because no trial has given a microdose. "Maintain results" is the part a reader is most likely to act on, and maintenance at a sub-therapeutic dose is exactly what nobody has studied.1
Dispensing chain
Who actually fills your prescription
Read the full account
No pharmacy is named. The clinical side is identified at the entity level — WizDoc LLC and Jonathan Larson, MD, P.C. — which is more than nothing, and no individual prescriber, credential or provider number is published, so none of it can be checked against a registry. The seller is SexyMD LLC, a Nevada limited liability company. One disclosure sits only in the Terms and is worth surfacing because it concerns what arrives at the door: prescriptions filled through the pharmacy network "will not be shipped in child-resistant packaging".
Read on the SexyMD site, September 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Nothing published on the pages searched
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
No certificate of analysis, potency, purity or sterility result is published. In place of it the site offers social proof that does not reconcile with itself: a badge reading "LOVED BY 800+ WOMEN" sits on both microdose pages, beside testimonials claiming specific outcomes — "Down 31 pounds in five months", "Down 18 pounds in 10 weeks" — and when we walked the checkout on 1 September 2026 it displayed counters reading "10,684 patients chose this today" and "17,126 patients chose this today". Those two figures add to 27,810 in a single day on a site whose own badge claims 800 customers in total. A placeholder page still carrying its unedited lorem ipsum filler text is also live and reachable on the site.
Read on the SexyMD site, September 2026.
Licensing
Licensed to dispense, and where
Coverage
The footer block, identical on all eleven pages, says both that the service "is available in all 50 states" and that services are "currently available in all states except Arkansas, Mississippi" and others. Those two sentences are in the same block, and a reader in an excluded state has no way to tell which governs.
Read the full licensing claim
Two clinical entities are named — WizDoc LLC and Jonathan Larson, MD, P.C. — and no individual prescriber, credential or provider number is published. The seller is SexyMD LLC, a Nevada limited liability company.
Read on the SexyMD site, September 2026.
Regulatory
The FDA warning letter
Checked, and none found
Assessment
What holds up, and what does not
- All prices are visible before any account, quiz or intake.
- The full-dose pages carry genuine plan-length tiers, and the commitment condition is stated on each row.
- Two clinical entities are named, which is more than many sellers in this market publish.
Show 2 more
- The instructions tab, once opened, gives a specific dosing rule and defers to the prescribing physician.
- No FDA warning letter against SexyMD LLC.
- The microdose GLP-1 + GIP page says the approach delivers the medication twice a week, and its instructions tab says once weekly.
- That contradiction is about injection frequency, on the page selling the injection.
- Its microdose "PRICES" table lists 4, 8 and 12 weeks at the same figure — a plan-length table where plan length changes nothing.
Show 9 more
- The same table format carries real tiers on the full-dose pages, so it reads as a discount structure that is not there.
- No completed randomized trial has tested a microdosed regimen of either molecule, at any frequency.
- "Same powerful GLP-1 mechanism, gentler on your body" asserts preserved effect and reduced burden, neither of which has been tested.
- A badge claiming 800+ customers sits beside checkout counters that claimed tens of thousands of orders in a single day.
- Testimonials give specific weight-loss figures with no sourcing.
- The footer says both that the service covers all 50 states and that several states are excluded, in the same block on all eleven pages.
- Only the Terms disclose that prescriptions are not shipped in child-resistant packaging.
- No pharmacy is named, and no individual clinician or credential is published.
- A placeholder page still carrying unedited lorem ipsum filler text is live on the site.
Verdict
The bottom line
Do not take your dosing schedule from this page. It explains microdosing as a twice-weekly injection in its body copy and instructs a once-weekly one in its how-to-use tab, and we saw both in the same session — get the frequency from the prescribing clinician in writing before you inject anything. Separately, if you are picking a microdose plan length expecting a discount, there isn't one: four, eight and twelve weeks are all the same monthly price.
Opens sexymd.com. A link is not a recommendation to take anything.
Two answers to one question
On SexyMD's Microdose GLP-1 + GIP page, in the copy explaining how the product works:
"The microdose approach delivers this twice a week so your body receives steady, consistent support without the intensity of a single large dose."
On the same page, under the tab headed HOW TO USE:
"Once-weekly subcutaneous injection, on the same day each week (unless instructed otherwise by your physician)."
Both were on screen in the same session on 2 September 2026.
The second sits behind a tab, and it is published — clicking the control reveals it, which is the standing test. Worth knowing if you check this yourself: a pass that clicks every button on the page indiscriminately does not open it and returns the benefits panel instead. You have to click "HOW TO USE" by name.
This is not two marketing sentences disagreeing about a benefit. It is two answers to how often a patient puts a needle in, on the page that sells the injection.
Full analysis — 4 more sectionsA price table with nothing in it · What microdosing has behind it · Numbers that do not reconcile · Two things only the Terms will tell you
A price table with nothing in it
The microdose pages carry a section headed PRICES:
| Plan | Microdose GLP-1 | Microdose GLP-1 + GIP | |---|---|---| | 4 weeks | $179/mo | $259/mo | | 8 weeks | $179/mo | $259/mo | | 12 weeks | $179/mo | $259/mo |
Three rows, one price.
That matters because the full-dose pages use the identical table format and it carries real tiers there — semaglutide runs $269 month-to-month down to $199 on a 48-week commitment, tirzepatide $369 down to $299. So a reader arriving at the microdose page sees the shape of a discount structure with no discount inside it.
What microdosing has behind it
Nothing, so far.
Searched on ClinicalTrials.gov with no status filter, "microdose semaglutide", "low-dose semaglutide", "microdose tirzepatide" and "low-dose tirzepatide" each return zero studies. A bare "tirzepatide" search in the same pass returns 293 records, so the zeros are a finding rather than a broken search. 1
Every trial in both programs used a once-weekly subcutaneous injection at a titrated dose. None tested a twice-weekly schedule, and none tested a dose held below the titration floor.
So the claim that carries the whole proposition —
"Same powerful GLP-1 mechanism, gentler on your body"
— asserts two things at once: that the effect survives the smaller dose, and that the burden falls. Neither has been measured, because no trial has given a microdose to anyone.
Numbers that do not reconcile
A badge on both microdose pages reads "LOVED BY 800+ WOMEN".
When we walked the checkout on 1 September 2026, it displayed "10,684 patients chose this today" on one product and "17,126 patients chose this today" on another. That is 27,810 orders in a single day, on a site claiming 800 customers in total.
The testimonials alongside give specific figures — "Down 31 pounds in five months", "Down 18 pounds in 10 weeks" — with no sourcing.
Two things only the Terms will tell you
That the service is, or is not, available in your state: the footer block on all eleven pages says both "available in all 50 states" and "available in all states except Arkansas, Mississippi" and others.
And that prescriptions filled through the pharmacy network "will not be shipped in child-resistant packaging" — disclosed in the Terms and nowhere a buyer is likely to look.
Questions
Frequently asked questions
How often am I supposed to inject the microdose?
The page does not settle it, which is the reason to be careful here. Its explanation of the approach says the medication is delivered twice a week; its how-to-use tab says a once-weekly subcutaneous injection on the same day each week. We saw both in the same session. Get the frequency in writing from the prescribing clinician before injecting anything.
Is a longer microdose plan cheaper?
No. Four, eight and twelve weeks are listed at the same monthly figure for both microdose products. The full-dose pages use the same table format and do carry real tiers there, which is why the microdose table reads like a discount structure that turns out to be empty.
Does microdosing work?
Nobody has published an answer. Searched with no status filter, ClinicalTrials.gov returns zero studies for microdosed or low-dose semaglutide and zero for tirzepatide, against 293 records for tirzepatide overall in the same pass. Every trial in both programs used a once-weekly injection at a titrated dose, so a dose held below that floor has not been tested for effect or for tolerability.
Is it available in my state?
The footer gives two answers in the same block, on all eleven pages: that the service is available in all 50 states, and that it is available in all states except Arkansas, Mississippi and others. Check before ordering rather than relying on the page.
Will my medication arrive in child-resistant packaging?
Not necessarily. The Terms state that prescriptions filled through the pharmacy network will not be shipped in child-resistant packaging. It appears there and not on any product page, and it is worth knowing if there are children in the house.
Who compounds and who prescribes?
The pharmacy is not named. The clinical side is identified only at the entity level — WizDoc LLC and Jonathan Larson, MD, P.C. — with no individual prescriber, credential or provider number published, so none of it can be checked against a registry.
Glossary
Key terms
Show definitions
- Microdosing
- Taking a dose below the range a drug was studied at. For GLP-1 medicines no completed randomized trial has tested one, so both the claimed benefit and the claimed gentleness are untested.
- Titration
- The stepped increase from a starting dose to a therapeutic one. The GLP-1 trials titrated to a target dose and reported results at that target; a dose held below the floor of the titration is outside what was measured.
Compare
Others selling what SexyMD sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Method
How we checked this
Non-product facts last checked September 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off SexyMD's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 1 sources
- US National Library of Medicine (2026). ClinicalTrials.gov, no status filter: "microdose semaglutide", "low-dose semaglutide", "microdose tirzepatide" and "low-dose tirzepatide" each 0 studies; control "tirzepatide" 293 records in the same pass. All trials in both programs used a once-weekly subcutaneous injection at a titrated dose. ClinicalTrials.gov. https://clinicaltrials.gov/search?intr=tirzepatide
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.